Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Armenia D, Forbici F, Bertoli A, Berno G, Malagnino V, Gagliardini R, Borghi V, Gennari W, Cicalini S, Buonomini A, Teti E, Lanini S, Latini A, Sarmati L, Mussini C, Andreoni M, Antinori A, Perno CF, Ceccherini-Silberstein F, Santoro MM. Armenia D, et al. Among authors: buonomini a. J Glob Antimicrob Resist. 2022 Sep;30:326-334. doi: 10.1016/j.jgar.2022.06.027. Epub 2022 Jul 3. J Glob Antimicrob Resist. 2022. PMID: 35793776 Free article.
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.
Nicastri E, Palmisano L, Sarmati L, D'Ettorre G, Parisi S, Andreotti M, Buonomini A, Pirillo FM, Narciso P, Bellagamba R, Vullo V, Montano M, Di Perri G, Andreoni M. Nicastri E, et al. Among authors: buonomini a. Curr HIV Res. 2008 May;6(3):261-6. doi: 10.2174/157016208784325010. Curr HIV Res. 2008. PMID: 18473790
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, D'Arrigo R, Buonomini AR, Van Marck H, Surdo M, Saccomandi P, Mostmans W, Aerssens J, Aquaro S, Stuyver LJ, Andreoni M, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. Antiviral Res. 2011 Apr;90(1):42-53. doi: 10.1016/j.antiviral.2011.02.005. Epub 2011 Feb 22. Antiviral Res. 2011. PMID: 21349294
Impact of pre-therapy viral load on virological response to modern first-line HAART.
Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastri E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Santoro MM, et al. Among authors: buonomini a. Antivir Ther. 2013;18(7):867-76. doi: 10.3851/IMP2531. Epub 2013 Jan 23. Antivir Ther. 2013. PMID: 23343501 Free article.
The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis.
Scognamiglio P, Chiaradia G, De Carli G, Giuliani M, Mastroianni CM, Aviani Barbacci S, Buonomini AR, Grisetti S, Sampaolesi A, Corpolongo A, Orchi N, Puro V, Ippolito G, Girardi E; SENDIH Study Group. Scognamiglio P, et al. Among authors: buonomini ar. BMC Infect Dis. 2013 Oct 10;13:473. doi: 10.1186/1471-2334-13-473. BMC Infect Dis. 2013. PMID: 24112129 Free PMC article.
36 results